Literature DB >> 19412129

Estrogen replacement increases matrix metalloproteinase contribution to vasoconstriction in a rat model of menopause.

Olga Lekontseva1, Yanyan Jiang, Sandra T Davidge.   

Abstract

OBJECTIVE: Estrogen deficiency has been implicated in the pathogenesis of postmenopausal hypertension; yet hormone replacement therapy has controversial effects on the cardiovascular risk. Surprisingly, the effects of estrogen in the aging vascular system have been understudied. Aging is associated with vascular inflammation [elevated tumor necrosis factor (TNF)]. TNF is an activator of matrix metalloproteinases (MMPs) that can have vasoactive properties by specific cleavage of big endothelin-1 (ET-1). We hypothesized that MMPs are downstream mediators of vascular dysfunction in aging/estrogen deficiency.
METHODS: Aged rats (12 months) were ovariectomized (to model a menopausal phenotype) and treated with placebo, estrogen or TNF inhibitor (etanercept) for 4 weeks. Reactivity of resistance mesenteric arteries was evaluated on pressure arteriograph and vascular MMP activity measured by gelatin zymography.
RESULTS: Vasoconstriction to big ET-1 was greater in menopausal (relative to cycling) phenotype, but attenuated with MMP inhibition. Estrogen replacement reduced sensitivity to big ET-1, whereas further increased the role of MMP in the constriction, which was not mediated by TNF. MMP-2 activity in the mesenteric vascular bed was greater in menopausal compared with cycling females, but returned to control levels after estrogen treatment.
CONCLUSIONS: Our study indicates that MMPs are critical modulators of endothelin-mediated vasoconstriction in aging/estrogen deficiency that was not evident in cycling animals. Estrogen replacement is complex: although it reduces MMP expression, estrogen leads to a greater acute MMP modulation of vascular function. Thus, understanding the novel role of estrogen as a regulator of vascular MMPs may provide valuable insights into women's cardiovascular health issues in aging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19412129     DOI: 10.1097/HJH.0b013e32832c41b5

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  12 in total

Review 1.  Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease.

Authors:  V B Gencel; M M Benjamin; S N Bahou; R A Khalil
Journal:  Mini Rev Med Chem       Date:  2012-02       Impact factor: 3.862

Review 2.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

3.  Estrogen-induced FOS-like 1 regulates matrix metalloproteinase expression and the motility of human endometrial and decidual stromal cells.

Authors:  Chao Chen; Congcong Li; Weichun Liu; Feng Guo; Xi Kou; Si Sun; Taiyang Ye; Shanji Li; Aimin Zhao
Journal:  J Biol Chem       Date:  2020-01-14       Impact factor: 5.157

4.  EMMPRIN-mediated induction of uterine and vascular matrix metalloproteinases during pregnancy and in response to estrogen and progesterone.

Authors:  Yiping Dang; Wei Li; Victoria Tran; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2013-07-13       Impact factor: 5.858

5.  Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones.

Authors:  Zongzhi Yin; Alaa A Sada; Ossama M Reslan; Neha Narula; Raouf A Khalil
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-04-10       Impact factor: 4.310

6.  Plasma matrix metalloproteinases and postmenopausal breast cancer risk: a nested case-control study in the Multiethnic Cohort study.

Authors:  Yeonju Kim; Nicholas J Ollberding; Yurii B Shvetsov; Adrian A Franke; Lynne R Wilkens; Gertraud Maskarinec; Brenda Y Hernandez; Loïc Le Marchand; Brian E Henderson; Laurence N Kolonel; Marc T Goodman
Journal:  Breast Cancer Res Treat       Date:  2012-10-31       Impact factor: 4.872

7.  Emergence of a metalloproteinase / phospholipase A2 axis of systemic inflammation.

Authors:  Carlos Fernandez-Patron; Dickson Leung
Journal:  Metalloproteinases Med       Date:  2015-08-13

8.  Effects of diosgenin on myometrial matrix metalloproteinase-2 and -9 activity and expression in ovariectomized rats.

Authors:  Chi-Chen Chang; Tang-Ching Kuan; Yao-Yuan Hsieh; Ying-Jui Ho; Yu-Ling Sun; Chih-Sheng Lin
Journal:  Int J Biol Sci       Date:  2011-07-13       Impact factor: 6.580

Review 9.  Therapeutic implications of estrogen for cerebral vasospasm and delayed cerebral ischemia induced by aneurysmal subarachnoid hemorrhage.

Authors:  Dale Ding; Robert M Starke; Aaron S Dumont; Gary K Owens; David M Hasan; Nohra Chalouhi; Ricky Medel; Chih-Lung Lin
Journal:  Biomed Res Int       Date:  2014-03-02       Impact factor: 3.411

10.  Knowledge-transfer learning for prediction of matrix metalloprotease substrate-cleavage sites.

Authors:  Yanan Wang; Jiangning Song; Tatiana T Marquez-Lago; André Leier; Chen Li; Trevor Lithgow; Geoffrey I Webb; Hong-Bin Shen
Journal:  Sci Rep       Date:  2017-07-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.